{
  "format_version": 3,
  "claim_natural": "Activation of cannabinoid receptor type 2 (CB2) on microglia has been proposed as a mechanism for modulating neuroinflammatory pain states, including chronic widespread pain syndromes such as fibromyalgia where central sensitization and microglial activation have been implicated (Cabral & Griffin-Thomas, 2009; Stella, 2010; Chen et al., 2023).",
  "claim_formal": {
    "subject": "the peer-reviewed literature on CB2-receptor activation on microglia, neuroinflammatory pain, and fibromyalgia, plus the three references the claim cites",
    "claim_type": "compound_empirical",
    "proof_direction": "affirm",
    "is_time_sensitive": false,
    "sub_claims": [
      {
        "id": "SC1",
        "property": "independently published peer-reviewed sources that propose or articulate CB2-receptor activation on microglia as a mechanism for modulating neuroinflammatory pain",
        "operator": ">=",
        "threshold": 3,
        "operator_note": "Counts independently published peer-reviewed sources that articulate the CB2-on-microglia / neuroinflammatory-pain mechanism. Threshold 3 is the standard consensus floor. The claim's phrase 'including ... fibromyalgia' is read as naming fibromyalgia as an INSTANCE of a neuroinflammatory pain state (a reading justified by SC2); SC1 therefore does NOT require a study that specifically proposed CB2-on-microglia agonism as a fibromyalgia therapy. The claim's verb 'has been proposed' is hedged, hypothesis-level language: the proof verifies that the mechanism has been proposed, NOT that it is a clinically proven fibromyalgia treatment."
      },
      {
        "id": "SC2",
        "property": "independently published peer-reviewed sources implicating central sensitization and microglial activation in fibromyalgia",
        "operator": ">=",
        "threshold": 3,
        "operator_note": "Counts independently published peer-reviewed sources implicating central sensitization and/or microglial activation in fibromyalgia. Threshold 3 is the standard consensus floor. The two phenomena are evaluated together because the claim conjoins them; the supporting set collectively covers both - microglial / glial activation (Findeisen et al. review; Albrecht et al. PET study) and central sensitization (Jurado-Priego et al. review, which names fibromyalgia explicitly). The verb 'have been implicated' is hedged."
      },
      {
        "id": "SC3",
        "property": "references named in the claim that resolve to a real, identifiable publication on the attributed topic",
        "operator": ">=",
        "threshold": 3,
        "operator_note": "Citation-integrity check - NOT a consensus count. The claim explicitly cites three references; threshold 3 means all three must resolve to a real, identifiable publication. Empirical facts sc3_cabral and sc3_stella confirm two of them (Cabral & Griffin-Thomas, 2009; Stella, 2010). There is NO empirical fact for the third reference, 'Chen et al., 2023', because systematic PubMed searches (adversarial check AC3) found no publication matching that citation on this topic. The absence of a third empirical fact is itself the evidence that SC3 fails: n_sc3 = 2 < 3."
      }
    ],
    "compound_operator": "AND",
    "operator_note": "The claim is taken as a complete unit - the sentence AND its parenthetical citation list - and decomposed into three sub-claims joined by AND. SC1 and SC2 test the two scientific propositions; SC3 tests the integrity of the three references the claim names. All three sub-claims must hold for the claim to be fully PROVED. The claim's verbs ('has been proposed', 'have been implicated') are deliberately hedged, hypothesis-level language; this proof verifies exactly that hedged form and does not test clinical efficacy."
  },
  "evidence": {
    "B1": {
      "type": "empirical",
      "label": "SC1: Cabral & Griffin-Thomas (2009) - CB2 localized to microglia",
      "sub_claim": "SC1",
      "source": {
        "name": "Cabral GA & Griffin-Thomas L (2009), 'Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation', Expert Reviews in Molecular Medicine 11:e3 (PubMed Central PMC2768535)",
        "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2768535/",
        "quote": "This expression of CB2 has been localized primarily to microglia, the resident macrophages of the CNS."
      },
      "verification": {
        "status": "verified",
        "method": "full_quote",
        "coverage_pct": null,
        "fetch_mode": "snapshot",
        "credibility": {
          "domain": "nih.gov",
          "source_type": "government",
          "tier": 5,
          "flags": [],
          "note": "Government domain (.gov)"
        }
      },
      "extraction": {
        "value": "verified",
        "value_in_quote": true,
        "quote_snippet": "This expression of CB2 has been localized primarily to microglia, the resident m"
      }
    },
    "B2": {
      "type": "empirical",
      "label": "SC1: Stella (2010) - CB2 on microglia; activation regulates microglial function",
      "sub_claim": "SC1",
      "source": {
        "name": "Stella N (2010), 'Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas', Glia 58(9):1017-1030 (PubMed Central PMC2919281)",
        "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2919281/",
        "quote": "These receptors are expressed by microglia, astrocytes and astrocytomas, and their activation regulates these cells\u2019 differentiation, functions and viability."
      },
      "verification": {
        "status": "verified",
        "method": "full_quote",
        "coverage_pct": null,
        "fetch_mode": "snapshot",
        "credibility": {
          "domain": "nih.gov",
          "source_type": "government",
          "tier": 5,
          "flags": [],
          "note": "Government domain (.gov)"
        }
      },
      "extraction": {
        "value": "verified",
        "value_in_quote": true,
        "quote_snippet": "These receptors are expressed by microglia, astrocytes and astrocytomas, and the"
      }
    },
    "B3": {
      "type": "empirical",
      "label": "SC1: Xu et al. (2023) - CB2 on activated microglia in spinal pain circuitry",
      "sub_claim": "SC1",
      "source": {
        "name": "Xu K, Wu Y, Tian Z, et al. (2023), 'Microglial Cannabinoid CB2 Receptors in Pain Modulation', International Journal of Molecular Sciences 24(3):2348 (PubMed Central PMC9917135)",
        "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9917135/",
        "quote": "Accumulating evidence has demonstrated that the expression of CB2 receptors is significantly increased in activated microglia in the spinal cord"
      },
      "verification": {
        "status": "verified",
        "method": "full_quote",
        "coverage_pct": null,
        "fetch_mode": "snapshot",
        "credibility": {
          "domain": "nih.gov",
          "source_type": "government",
          "tier": 5,
          "flags": [],
          "note": "Government domain (.gov)"
        }
      },
      "extraction": {
        "value": "verified",
        "value_in_quote": true,
        "quote_snippet": "Accumulating evidence has demonstrated that the expression of CB2 receptors is s"
      }
    },
    "B4": {
      "type": "empirical",
      "label": "SC2: Findeisen et al. (2025) - maladaptive microglial activation in fibromyalgia",
      "sub_claim": "SC2",
      "source": {
        "name": "Findeisen K, Guymer E, Littlejohn G (2025), 'Neuroinflammatory and Immunological Aspects of Fibromyalgia', Brain Sciences 15(2):206 (PubMed Central PMC11852494)",
        "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11852494/",
        "quote": "There is a growing focus on processes occurring in the dorsal root ganglia and the role of maladaptive microglial cell activation."
      },
      "verification": {
        "status": "verified",
        "method": "full_quote",
        "coverage_pct": null,
        "fetch_mode": "snapshot",
        "credibility": {
          "domain": "nih.gov",
          "source_type": "government",
          "tier": 5,
          "flags": [],
          "note": "Government domain (.gov)"
        }
      },
      "extraction": {
        "value": "verified",
        "value_in_quote": true,
        "quote_snippet": "There is a growing focus on processes occurring in the dorsal root ganglia and t"
      }
    },
    "B5": {
      "type": "empirical",
      "label": "SC2: Albrecht et al. (2019) - PET evidence of brain glial activation in fibromyalgia",
      "sub_claim": "SC2",
      "source": {
        "name": "Albrecht DS, Forsberg A, Sandstrom A, et al. (2019), 'Brain glial activation in fibromyalgia - A multi-site positron emission tomography investigation', Brain, Behavior, and Immunity 75:72-83 (PubMed Central PMC6541932)",
        "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6541932/",
        "quote": "While mounting evidence suggests a role for neuroinflammation, no study has directly provided evidence of brain glial activation in FM."
      },
      "verification": {
        "status": "verified",
        "method": "full_quote",
        "coverage_pct": null,
        "fetch_mode": "snapshot",
        "credibility": {
          "domain": "nih.gov",
          "source_type": "government",
          "tier": 5,
          "flags": [],
          "note": "Government domain (.gov)"
        }
      },
      "extraction": {
        "value": "verified",
        "value_in_quote": true,
        "quote_snippet": "While mounting evidence suggests a role for neuroinflammation, no study has dire"
      }
    },
    "B6": {
      "type": "empirical",
      "label": "SC2: Jurado-Priego et al. (2024) - central sensitization as a process in fibromyalgia",
      "sub_claim": "SC2",
      "source": {
        "name": "Jurado-Priego LN, Cueto-Urena C, Ramirez-Exposito MJ, Martinez-Martos JM (2024), 'Fibromyalgia: A Review of the Pathophysiological Mechanisms and Multidisciplinary Treatment Approaches', Biomedicines 12(7):1543 (PubMed Central PMC11275111)",
        "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11275111/",
        "quote": "three underlying processes in fibromyalgia have been investigated. These include central sensitization, associated with an increase in the release of both excitatory and inhibitory neurotransmitters"
      },
      "verification": {
        "status": "verified",
        "method": "full_quote",
        "coverage_pct": null,
        "fetch_mode": "snapshot",
        "credibility": {
          "domain": "nih.gov",
          "source_type": "government",
          "tier": 5,
          "flags": [],
          "note": "Government domain (.gov)"
        }
      },
      "extraction": {
        "value": "verified",
        "value_in_quote": true,
        "quote_snippet": "three underlying processes in fibromyalgia have been investigated. These include"
      }
    },
    "B7": {
      "type": "empirical",
      "label": "SC3: cited reference 1 - Cabral & Griffin-Thomas (2009) resolves to a real publication",
      "sub_claim": "SC3",
      "source": {
        "name": "PubMed Central bibliographic record for Cabral & Griffin-Thomas (2009), PMC2768535",
        "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2768535/",
        "quote": "Expert Rev Mol Med. 2009 Jan 20;11:e3. doi: 10.1017/S1462399409000957"
      },
      "verification": {
        "status": "verified",
        "method": "full_quote",
        "coverage_pct": null,
        "fetch_mode": "snapshot",
        "credibility": {
          "domain": "nih.gov",
          "source_type": "government",
          "tier": 5,
          "flags": [],
          "note": "Government domain (.gov)"
        }
      },
      "extraction": {
        "value": "verified",
        "value_in_quote": true,
        "quote_snippet": "Expert Rev Mol Med. 2009 Jan 20;11:e3. doi: 10.1017/S1462399409000957"
      }
    },
    "B8": {
      "type": "empirical",
      "label": "SC3: cited reference 2 - Stella (2010) resolves to a real publication",
      "sub_claim": "SC3",
      "source": {
        "name": "PubMed Central bibliographic record for Stella (2010), PMC2919281",
        "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2919281/",
        "quote": "Glia. 2010 Jul;58(9):1017-1030. doi: 10.1002/glia.20983"
      },
      "verification": {
        "status": "verified",
        "method": "full_quote",
        "coverage_pct": null,
        "fetch_mode": "snapshot",
        "credibility": {
          "domain": "nih.gov",
          "source_type": "government",
          "tier": 5,
          "flags": [],
          "note": "Government domain (.gov)"
        }
      },
      "extraction": {
        "value": "verified",
        "value_in_quote": true,
        "quote_snippet": "Glia. 2010 Jul;58(9):1017-1030. doi: 10.1002/glia.20983"
      }
    },
    "A1": {
      "type": "computed",
      "label": "SC1 verified-source count",
      "sub_claim": "SC1",
      "method": "count(verified SC1 citations) = 3",
      "result": "3",
      "depends_on": [
        "B1",
        "B2",
        "B3"
      ]
    },
    "A2": {
      "type": "computed",
      "label": "SC2 verified-source count",
      "sub_claim": "SC2",
      "method": "count(verified SC2 citations) = 3",
      "result": "3",
      "depends_on": [
        "B4",
        "B5",
        "B6"
      ]
    },
    "A3": {
      "type": "computed",
      "label": "SC3 resolved-citation count",
      "sub_claim": "SC3",
      "method": "count(cited references resolving to a real publication) = 2; the claim names 3 references, so n_sc3 < 3 means at least one citation is unverifiable",
      "result": "2",
      "depends_on": [
        "B7",
        "B8"
      ]
    }
  },
  "cross_checks": [
    {
      "description": "SC1: independent peer-reviewed sources for the CB2/microglia mechanism",
      "fact_ids": [
        "B1",
        "B2",
        "B3"
      ],
      "agreement": true,
      "n_sources_consulted": 3,
      "n_sources_verified": 3,
      "sources": {
        "sc1_cabral": "verified",
        "sc1_stella": "verified",
        "sc1_xu": "verified"
      },
      "independence_note": "Three separate publications, distinct author groups, spanning 2009-2023; no shared authorship and no COI with a commercial subject.",
      "coi_flags": []
    },
    {
      "description": "SC2: independent peer-reviewed sources for fibromyalgia neuro-immune features",
      "fact_ids": [
        "B4",
        "B5",
        "B6"
      ],
      "agreement": true,
      "n_sources_consulted": 3,
      "n_sources_verified": 3,
      "sources": {
        "sc2_brainsci": "verified",
        "sc2_albrecht": "verified",
        "sc2_jurado": "verified"
      },
      "independence_note": "A 2025 narrative review, a 2019 multi-site PET primary study, and a 2024 pathophysiology review - distinct author groups; collectively cover microglial activation and central sensitization.",
      "coi_flags": []
    },
    {
      "description": "SC3: do the three references named in the claim resolve to real publications?",
      "fact_ids": [
        "B7",
        "B8"
      ],
      "agreement": false,
      "n_sources_consulted": 3,
      "n_sources_verified": 2,
      "sources": {
        "sc3_cabral": "verified",
        "sc3_stella": "verified"
      },
      "independence_note": "Two of the three named references resolve and verify (Cabral & Griffin-Thomas 2009; Stella 2010). The third, 'Chen et al., 2023', was searched systematically in PubMed and could not be identified - see adversarial check AC3. n_sc3 = 2 < 3.",
      "coi_flags": []
    }
  ],
  "adversarial_checks": [
    {
      "question": "Is the CB2-on-microglia mechanism for neuroinflammatory pain a genuine, proposed research mechanism - or is it fringe / disputed?",
      "verification_performed": "Searched PubMed and the web for reviews and primary literature on CB2 receptors, microglia and pain ('CB2 microglia pain modulation', 'cannabinoid CB2 neuroinflammation', 'cannabinoid fibromyalgia efficacy'). Cross-checked whether cannabinoids are an established fibromyalgia treatment.",
      "finding": "The CB2-on-microglia mechanism for modulating neuroinflammatory pain is a well-established research hypothesis, articulated across many independent peer-reviewed reviews from 2009 to 2023 - not a fringe claim. Counter-point: clinical efficacy of cannabinoids in fibromyalgia SPECIFICALLY remains inconsistent and unproven. This does not break SC1, because the claim asserts only that the mechanism 'has been proposed' (hypothesis-level language), not that it is a clinically proven treatment; the hedged wording is accurate. The unproven-efficacy point is recorded so the claim is not over-read.",
      "breaks_proof": false
    },
    {
      "question": "Is microglial activation in fibromyalgia disputed - e.g. is the Albrecht et al. (2019) glial-activation PET finding contradicted?",
      "verification_performed": "Searched for replication and criticism of glial-activation findings in fibromyalgia ('fibromyalgia microglia PET criticism', 'fibromyalgia neuroinflammation replication', 'TSPO PET limitations').",
      "finding": "TSPO-PET evidence of glial activation in fibromyalgia has acknowledged limitations (the TSPO tracer is not microglia-specific; sample sizes are modest), and it remains an area of active research. But the broader implication - that neuroinflammation / microglial activation and central sensitization are involved in fibromyalgia - is supported by converging evidence (PET imaging, CSF cytokines, multiple narrative reviews). No authoritative source rejects the implication. The claim's verb 'have been implicated' is appropriately hedged, so the TSPO caveats do not break SC2.",
      "breaks_proof": false
    },
    {
      "question": "Does the cited reference 'Chen et al., 2023' correspond to a real, identifiable publication supporting the attributed content?",
      "verification_performed": "Systematic PubMed searches via NCBI E-utilities and the PubMed web interface: (1) Chen[au] AND 2023[dp] AND (CB2 OR cannabinoid) AND microglia AND pain -> 1 hit, Chen L et al., 'Assessing Cannabidiol as a Therapeutic Agent for Preventing and Alleviating Alzheimer's Disease Neurodegeneration', Cells 2023 (off-topic: cannabidiol / Alzheimer's, not CB2 / microglia / pain). (2) Chen[au] AND 2023[dp] AND cannabinoid AND microglia -> 7 hits, no Chen-first-author paper on CB2 / microglia / pain. (3) Chen[au] AND 2023[dp] AND fibromyalgia -> 25 hits, none a Chen-first-author cannabinoid / CB2 / microglia paper. (4) Chen[au] AND 2023[dp] AND CB2 AND pain -> 1 hit, first author Nan, not Chen. Web searches likewise surfaced the only on-topic 2023 review, 'Microglial Cannabinoid CB2 Receptors in Pain Modulation' (first author Xu, not Chen), and 'Spinal cannabinoid receptor 2 activation alleviates neuropathic pain by regulating microglia' (first author Zhou, not Chen). PubMed query URLs: https://pubmed.ncbi.nlm.nih.gov/?term=Chen%5Bau%5D+AND+2023%5Bdp%5D+AND+cannabinoid+AND+microglia ; https://pubmed.ncbi.nlm.nih.gov/?term=Chen%5Bau%5D+AND+2023%5Bdp%5D+AND+fibromyalgia",
      "finding": "No publication matching 'Chen et al., 2023' on CB2 / microglia / neuroinflammatory pain or fibromyalgia could be identified. The two genuinely on-topic 2023 papers have first authors Xu and Zhou, not Chen. This is the evidence underlying SC3's failure: one of the three references named in the claim is unverifiable, a pattern consistent with a misattributed or fabricated (hallucinated) citation. It does NOT break the proof and is not forced to UNDETERMINED, because SC1 and SC2 are independently established and SC3's failure is already captured by the compound verdict. breaks_proof is therefore False.",
      "breaks_proof": false
    },
    {
      "question": "Does the claim require a source that specifically proposed CB2-on-microglia modulation as a fibromyalgia treatment?",
      "verification_performed": "Re-read the claim's grammar and searched for CB2 / microglia proposals targeting fibromyalgia specifically ('CB2 receptor microglia fibromyalgia', 'endocannabinoid system fibromyalgia').",
      "finding": "Under the natural reading, 'including chronic widespread pain syndromes such as fibromyalgia' names fibromyalgia as an INSTANCE of the neuroinflammatory pain states for which the mechanism is proposed - a reading bridged by SC2, which establishes that fibromyalgia is characterized by central sensitization and microglial activation. The claim does not assert that a specific study tested CB2-on-microglia agonism in fibromyalgia patients, and this proof does not rely on one. A stricter reading (a dedicated fibromyalgia-specific CB2/microglia proposal) would be only weakly supported; that scope limitation is disclosed here and in proof.md. It does not change the verdict, which already reports SC3's failure.",
      "breaks_proof": false
    }
  ],
  "verdict": {
    "value": "PARTIALLY VERIFIED",
    "qualified": false,
    "qualifier": null,
    "reason": null
  },
  "key_results": {
    "n_holding": 2,
    "n_total": 3,
    "claim_holds": false,
    "sc1_holds": true,
    "sc2_holds": true,
    "sc3_holds": false,
    "unidentified_citation": "Chen et al., 2023"
  },
  "generator": {
    "name": "proof-engine",
    "version": "1.34.1",
    "repo": "https://github.com/yaniv-golan/proof-engine",
    "generated_at": "2026-05-20"
  },
  "sub_claim_results": [
    {
      "id": "SC1",
      "n_confirming": 3,
      "threshold": 3,
      "holds": true
    },
    {
      "id": "SC2",
      "n_confirming": 3,
      "threshold": 3,
      "holds": true
    },
    {
      "id": "SC3",
      "n_confirming": 2,
      "threshold": 3,
      "holds": false
    }
  ],
  "verdict_note": "PARTIALLY VERIFIED: the two scientific propositions (SC1, SC2) are verified and well-supported; the citation-integrity sub-claim (SC3) fails because one of the three references the claim names, 'Chen et al., 2023', could not be identified as a real publication.",
  "proof_py_url": "/proofs/activation-of-cannabinoid-receptor-type-2-cb2-on-microglia-has-been-proposed-as/proof.py",
  "citation": {
    "doi": "10.5281/zenodo.20318616",
    "concept_doi": "10.5281/zenodo.20314488",
    "url": "https://proofengine.info/proofs/activation-of-cannabinoid-receptor-type-2-cb2-on-microglia-has-been-proposed-as/",
    "author": "Proof Engine",
    "cite_bib_url": "/proofs/activation-of-cannabinoid-receptor-type-2-cb2-on-microglia-has-been-proposed-as/cite.bib",
    "cite_ris_url": "/proofs/activation-of-cannabinoid-receptor-type-2-cb2-on-microglia-has-been-proposed-as/cite.ris"
  },
  "depends_on": [
    {
      "relation": "References",
      "identifiers": [
        {
          "type": "pmc",
          "value": "PMC2768535"
        },
        {
          "type": "doi",
          "value": "10.1017/S1462399409000957"
        }
      ],
      "note": "Cabral & Griffin-Thomas (2009) \u2014 CB2 localized to microglia"
    },
    {
      "relation": "References",
      "identifiers": [
        {
          "type": "pmc",
          "value": "PMC2919281"
        },
        {
          "type": "doi",
          "value": "10.1002/glia.20983"
        }
      ],
      "note": "Stella (2010) \u2014 CB1/CB2 on microglia"
    },
    {
      "relation": "References",
      "identifiers": [
        {
          "type": "doi",
          "value": "10.1002/glia"
        }
      ],
      "note": "Stella (2010) \u2014 truncated DOI form captured by prose-scan regex (separate follow-up; not a real DOI)"
    },
    {
      "relation": "References",
      "identifiers": [
        {
          "type": "pmc",
          "value": "PMC9917135"
        }
      ],
      "note": "Xu et al. (2023) \u2014 Microglial CB2 in pain modulation"
    },
    {
      "relation": "References",
      "identifiers": [
        {
          "type": "pmc",
          "value": "PMC11852494"
        }
      ],
      "note": "Findeisen et al. (2025) \u2014 Fibromyalgia neuroinflammation"
    },
    {
      "relation": "References",
      "identifiers": [
        {
          "type": "pmc",
          "value": "PMC6541932"
        }
      ],
      "note": "Albrecht et al. (2019) \u2014 TSPO-PET glial activation in fibromyalgia"
    },
    {
      "relation": "References",
      "identifiers": [
        {
          "type": "pmc",
          "value": "PMC11275111"
        }
      ],
      "note": "Jurado-Priego et al. (2024) \u2014 Fibromyalgia pathophysiology"
    }
  ]
}